|
| Population | All strokes and SEE | Major bleeding |
| Comparison | Risk difference
(95% CI) | NNTB
(95% CI) | Risk difference
(95% CI) | NNTB
(95% CI) |
|
| All patients | | | | |
| All NOAC versus warfarin | −3.2 (−4.8 to −1.6) | 310 (207 to 620) | −4 (−9 to 1) | 253 (NNTB 111 to ∞ to NNTH 962) |
| Dabigatran versus warfarin | −3.7 (−6.5 to −1) | 269 (154 to 980) | −4.4 (−8.4 to −0.5) | 228 (120 to 2179) |
| Rivaroxaban versus warfarin | −2.7 (−6 to 0.7) | 370 (NNTB 166 to ∞ to NNTH 1479) | 0.7 (−3.2 to 4.5) | NNTH 1479 (NNTB 310 to ∞ to NNTH 221) |
| Apixaban versus warfarin | −3.3 (−5.9 to −0.7) | 303 (168 to 1374) | −8.4 (−11.7 to −5.1) | 119 (85 to 196) |
|
| European population | | | | |
| All NOAC versus warfarin | −0.9 (−3.1 to 1.4) | 1131 (NNTB 321 to ∞ to NNTH 712) | −3.0 (−5.7 to −0.3) | 337 (176 to 3846) |
| Dabigatran versus warfarin | −0.6 (−4.6 to 3.5) | 1783 (NNTB 218 to ∞ to NNTH 288) | −3.2 (−8.4 to 2.1) | 316 (NNTB 119 to ∞ to NNTH 467) |
| Rivaroxaban versus warfarin | −2.3 (−7 to 2.3) | 437 (NNTB 145 to ∞ to NNTH 437) | −2.1 (−6.7 to 2.3) | 469 (NNTB 150 to ∞ to NNTH 427) |
| Apixaban versus warfarin | −0.3 (−4 to 3.4) | 2976 (NNTB 252 to ∞ to NNTH 298) | −3.8 (−8.4 to 0.9) | 263 (NNTB 119 to ∞ to NNTH 1276) |
|
| Non-European population | | | | |
| All NOAC versus warfarin | −4.9 (−7.1 to −2.7) | 205 (140 to 377) | −4.3 (−12.5 to 3.9) | 232 (NNTB 80 to ∞ to NNTH 256) |
| Dabigatran versus warfarin | −5.7 (−9.3 to −2) | 177 (108 to 503) | −5.2 (−10.7 to 0.3) | 192 (NNTB 94 to ∞ to NNTH 3922) |
| Rivaroxaban versus warfarin | −3.1 (−8.1 to 1.9) | 321 (NNTB 123 to ∞ to NNTH 534) | 4 (−2.6 to 10.5) | NNTH 253 (NNTB 385 to ∞ to NNTH 95) |
| Apixaban versus warfarin | −5.4 (−9 to −1.8) | 186 (112 to 558) | −11.5 (−16.1 to −6.9) | 87 (62 to 144) |
|
| Prior stroke or TIA | | | | |
| All NOAC versus warfarin | −3.6 (−7.4 to 0.1) | 275 (NNTB 135 to ∞ to NNTH 19231) | −4.1 (−8.7 to 0.6) | 247 (NNTB 114 to ∞ to NNTH 1603) |
| Dabigatran versus warfarin | −5.5 (−13.2 to 2.3) | 183 (NNTB 76 to ∞ to NNTH 436) | −6.3 (−15.8 to 3.1) | 158 (NNTB 63 to ∞ to NNTH 321) |
| Rivaroxaban versus warfarin | −1.4 (−6.5 to 3.7) | 712 (NNTB 154 to ∞ to NNTH 271) | −1 (−6 to 4.1) | 1012 (NNTB 166 to ∞ to NNTH 243) |
| Apixaban versus warfarin | −7.4 (−15.5 to 0.7) | 135 (NNTB 64 to ∞ to NNTH 1374) | −8.6 (−17 to −0.2) | 116 (59 to 4464) |
|
| No prior stroke or TIA | | | | |
| All NOAC versus warfarin | −2.9 (−4.6 to −1.2) | 350 (219 to 836) | −3.5 (−9.1 to 2) | 283 (NNTB 111 to ∞ to NNTH 506) |
| Dabigatran versus warfarin | −3.3 (−6.2 to −0.5) | 302 (162 to 1961) | −3.9 (−3.2 to 0.4) | 255 (NNTB 316 to ∞ to NNTH 2451) |
| Rivaroxaban versus warfarin | −4.3 (−8.5 to 0) | 235 (117 to ∞) | 2.6 (−3.4 to 8.5) | NNTH 392 (NNTB 291 to ∞ to NNTH 118) |
| Apixaban versus warfarin | −2.2 (−4.8 to 3.0) | 446 (NNTB 208 to ∞ to NNTH 2976) | −8.3 (−11.9 to −0.5) | 121 (84 to 213) |
|
| TTR ≥ 65% | | | | |
| All NOAC versus warfarin | −2.6 (−4.8 to −0.4) | 385 (207 to 2404) | −0.6 (−6.6 to 7.7) | NNTH 1748 (NNTB 153 to ∞ to NNTH 130) |
| Dabigatran versus warfarin | −2 (−5.7 to 1.6) | 490 (NNTB 177 to ∞ to NNTH 633) | 0.1 (−5.4 to 5.7) | NNTH 9804 (NNTB 185 to ∞ to NNTH 177) |
| Rivaroxaban versus warfarin | −4.2 (−9.7 to 1.3) | 240 (NNTB 103 to ∞ to NNTH 769) | 9.1 (0.2 to 17.9) | NNTH 111 (56 to 4808) |
| Apixaban versus warfarin | −2.7 (−6.1 to 0.7) | 372 (NNTB 165 to ∞ to NNTH 1488) | −5.4 (−10.4 to −0.4) | 186 (97 to 2551) |
|
| TTR < 65% | | | | |
| All NOAC versus warfarin | −4 (−6.2 to −1.9) | 250 (162 to 534) | −7.1 (−12.7 to −1.6) | 140 (78 to 641) |
| Dabigatran versus warfarin | −5.3 (−9.4 to −1.2) | 189 (107 to 853) | −8.8 (−14.4 to −3.2) | 113 (69 to 316) |
| Rivaroxaban versus warfarin | −3.3 (−6.9 to 0.2) | 300 (NNTB 146 to ∞ to NNTH 6410) | −2 (−6.3 to 2.3) | 493 (NNTB 159 to ∞ to NNTH 437) |
| Apixaban versus warfarin | −4 (−8 to 0) | 252 (126 to ∞) | −11.4 (−15.8 to −7) | 88 (63 to 143) |
|
